Search research articles
Contact Us
Filters
Showing results (11-20 of 32) with videos related to
Page
of 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2001
A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer
K N Chi, M E Gleave, R Klasa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 31, 2014
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial
C N Sternberg, J S de Bono, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2011
A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a
K N Chi, E Beardsley, B J Eigl, et al.
Investigational New Drugs
|
September 28, 2013
NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies
S F Dent, K A Gelmon, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2016
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
K N Chi, E Y Yu, C Jacobs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 27, 2014
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
M R Smith, R E Coleman, L Klotz, et al.
Cancer Chemotherapy and Pharmacology
|
July 4, 2012
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
A W Tolcher, K N Chi, N D Shore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 7, 2007
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
K N Chi, S L Ellard, S J Hotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2005
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group
C M Canil, M J Moore, E Winquist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 19, 2004
A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131
K A Gelmon, D Stewart, K N Chi, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 32) with videos related to
Sort By:
Page
of 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2001
A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer
K N Chi, M E Gleave, R Klasa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 31, 2014
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial
C N Sternberg, J S de Bono, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2011
A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a
K N Chi, E Beardsley, B J Eigl, et al.
Investigational New Drugs
|
September 28, 2013
NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies
S F Dent, K A Gelmon, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2016
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
K N Chi, E Y Yu, C Jacobs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 27, 2014
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
M R Smith, R E Coleman, L Klotz, et al.
Cancer Chemotherapy and Pharmacology
|
July 4, 2012
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
A W Tolcher, K N Chi, N D Shore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 7, 2007
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
K N Chi, S L Ellard, S J Hotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2005
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group
C M Canil, M J Moore, E Winquist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 19, 2004
A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131
K A Gelmon, D Stewart, K N Chi, et al.
Page
of 4